LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
Dateline City:
KENILWORTH, N.J.
Improved the Median Time to Disease Progression (37.2 months) vs. Bevacizumab Alone (17.7 months) Following Response to Platinum-Based Chemotherapy with Bevacizumab
Approximately One in Two Women with Advanced Ovarian Cancer Has an HRD-Positive Tumor
KENILWORTH, N.J.–(BUSINESS WIRE)–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.
Language:
English
Contact:
Media:
Pamela Eisele
(267) 305-3558
Steve Wanczyk
(267) 305-556
Investors:
Peter Dannenbaum
(908) 740-1037
Courtney Ronaldo
(908) 740-6132
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck
